



STDR
Singapore Therapeutics
Development Review



Launch of STDR 2024 (May) & Attributes of Successful Applications

STDR CO
May 2024



CREATING GROWTH, ENHANCING LIVES



Agency for
Science, Technology
and Research
SINGAPORE



Experimental
Drug Development
Centre



Singapore-MIT Alliance for Research and Technology



Pilot Grant Call Launch

STDR Pilot (May) Launch Dates and Admin Notes



Call for Pilot Proposals

- **13 May 2024:** Launch of 2024 (May) Pilot grant call on iGrants
- **27 Jun 2024, 5pm:** Deadline for submissions of proposals

All proposals must be endorsed by the IEO office and Research Director.

Shortlisted applicants will be notified of the outcome (tentatively around mid-Sep 2024) and requested to submit pitch deck and revised proposal.



Eligibility criteria

The Lead Principal Investigator (PI) should:

- a) Hold at least a 0.7 FTE primary appointment in a Singapore publicly funded research/ tertiary institution
- b) Have the relevant scientific/technical background and necessary experience to direct the project being supported by the grant.

Post-doctoral researchers should submit a letter from their supervisor declaring that:

- a) The supervisor supports the application
- b) The contract of the post-doc covers the entire STDR grant period
- c) The grant body funding the post-doc is agreeable to the STDR application (if relevant).

(Exceptions to the eligibility criteria will be considered on a case-by-case basis.)

STDR Pilot Phases 1 & 2

- Up to **S\$830K** may be awarded for Pilot Phase 1 and Phase 2 funding.







Phase 1	Phase 2
<ul style="list-style-type: none">• Achievement of key go/no-go milestone(s) that e.g. show progress or reduce risk/uncertainty• Up to S\$330K*• Maximum of 1 year	<ul style="list-style-type: none">• Achievement of remaining key milestones that bring research to next value inflection point, ideally ready for commercialisation• Up to S\$500K*• Maximum of 1 year

- Applicants are encouraged to **accelerate** the project where reasonable. If milestones are achieved ahead of timeline, please write to STDR Secretariat to discuss repurposing of leftover fund (if any) and earlier unlocking of Phase 2 funding.

*Including 30% indirect costs

Attributes of Strong Proposals

General Attributes of Strong Applications

Strategic Positioning		Why?	Compelling reason for why the proposed work is relevant
		What?	Sufficient data to show clarity in the product's role in the disease indication
		TPP (Target Product Profile)	A framework of the product's properties, who will use it , and the competitive advantage
Execution Planning		Development Plan	Realistic plan with critical experiments , points of go/no-go decisions , value inflection points that demonstrate progress or reduce uncertainty
		Who?	A multidisciplinary team with strong expertise in relevant areas
		Commercialisation strategy	Describe the business model with specifics and context

Attributes of Strong Pilot Applications – Single Assets



Research and Scientific Merit

- **Efficacy against a validated target** with strong hypothesis of MoA
- **Scientific insight into prior work** through peer-reviewed publications
- **Acceptable safety profile** or plan for toxicity study



Strong Medical Need and Market Evaluation

- **Address an unmet need**
- **Differentiated** and significant benefit to current standard of care and/or competitors
- **A global market** and many opportunities preferred



Clear Development Plan

- Clarity of a **path towards first in-human use**
- **Regulatory path** knowledge



Strong Commercialisation Plan

- Strong opportunities to create **intellectual property**
- Possibilities of **strategic partnerships**

Attributes of Strong Pilot Applications – Platform Technologies



Research and Scientific Merit

- Supporting data to show that platform is capable of making **multiple products**
- **Proof-of-Concept** to show platform application in suitable market/indication



Strong Medical Need and Market Evaluation

- Address **unmet medical need**
- **Critical attributes** of the platform
- **Differentiating factors** and advantages of the platform and lead product



Commercialisation Strategy

- **Identification of the risks** and mitigation plan
- What is the **value chain** and who is the ultimate user or payer
- What is required to **scale the platform**

Resubmission Strategy



- **Successful resubmissions**

- ✓ **Address reviewers' comments** and make appropriate **changes**.
- ✓ **Rewritten** with **additional data** presented.
- ✓ **More outstanding factors** (e.g. greater commercialisation potential, potential to expand into other indications).
- ✓ **Good progress** since the last review.



- **Unsuccessful resubmissions**

- **Lack certain key aspects** (e.g. a compelling differentiating factor or sufficient commercialisation potential).
- **Lack significant progress** since last review.

Summary



STDR Pilot grant call: 13 May – 27 Jun 2024 on iGrants



General Attributes of Strong STDR Applications

1. Why?
2. What?
3. Target Product Profile (TPP)
4. Development Plan
5. Who?
6. Commercialisation Strategy

Contact us

Email:

stdr_secretariat@hq.a-star.edu.sg

Website:

<https://www.a-star.edu.sg/Research/funding-opportunities/stdr>





CREATING GROWTH, ENHANCING LIVES



THANK YOU

www.a-star.edu.sg